Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting

Eli Lilly’s experimental obesity pill allowed patients who had lost weight on injected GLP-1-based drugs to keep most of the weight off for another year, according to data from a Phase 3 trial